Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell Neoplasms

You may be eligible if

• WBC \< 50,000/mm\^3 for patients with circulating tumor cells
• No prior allergic reaction to compounds of similar chemical or biological composition to and presumably able to tolerated bortezomib, flavopiridol, allopurinol, sodium polystyrene sulfonate, or dexamethasone
• No neuropathy \>= grade 2
• No other condition that would preclude study participation
• Not pregnant or nursing
• Fertile patients must use effective contraception during and for 3 months after study participation
• Prior autologous stem cell transplantation is allowed
• No prior allogeneic stem cell transplantation
• No other concurrent anticancer agents
• No other concurrent investigational agents
• Hemoglobin \>= 8 g/dL
• Platelet count \>= 100,000/mm\^3
• Absolute neutrophil count \>= 1,500/mm\^3
• Bilirubin =\< 2 times upper limit of normal (ULN)
• AST/ALT =\< 3 times ULN
• Creatinine =\< 2 times ULN or Creatinine clearance \>= 50 mL/min